Oral Presentation Lancefield International Symposium for Streptococci and Streptococcal Diseases 2025

Adjuvant optimisation is crucial for protective efficacy and immunogenicity of the Group A Streptococcus vaccine candidates Combo#5 and VAX-A1 (118232)

Johanna Richter 1 , Charles W Armitage 2 , Anca Grivei 2 , Michael Nissen 2 , Jad Farouqa 2 , Ismail Sebina 2 , Rhiannon A Bolton 2 , Isabel G Courtney 2 , Paresh Agarwal 3 , Mollie Jacobs 3 , Michelle Stroud 3 , Celine Lemoine 4 , Falko Apel 4 , Virginie Jakob 4 , Maria Lawrenz 4 , Nichaela Harbison-Price 1 , Amanda J Cork 1 , Gayathiri Elangovan 1 , Jack Na 1 , Laura Davis 1 , Brody Pullinger 1 , Khanh Nguyen 1 , Miguel Aguirre 1 , Victor Nizet 5 , Patrice Dubois 4 , Nicolas Collin 4 , Neeraj Kapoor 3 , Gabrielle T Belz 2 , Mark J Walker 1
  1. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
  2. Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia
  3. Vaxcyte Inc., San Carlos, California, USA
  4. Vaccine Formulation Institute, Plan-les-Ouates, Switzerland
  5. Department of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California - San Diego, La Jolla, California, USA
Publish consent withheld